In contrast to biallelic MCM8/MCM9 variant carriers, our current data suggest that the phenotype of monoallelic MCM8/MCM9 variant carriers may primarily be limited to hypogonadism, with no clear evidence of an increased cancer risk, which does not seem to justify cancer surveillance for these individuals. This evidence concerns the gene MCM9 and cancer.